PGE


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
24 Apr 2024
Historique:
received: 22 05 2023
accepted: 26 03 2024
medline: 25 4 2024
pubmed: 25 4 2024
entrez: 24 4 2024
Statut: aheadofprint

Résumé

Expansion of antigen-experienced CD8

Identifiants

pubmed: 38658764
doi: 10.1038/s41586-024-07352-w
pii: 10.1038/s41586-024-07352-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328–1334 (2020).
pubmed: 33303615 pmcid: 8883579 doi: 10.1126/science.abb9847
Codarri Deak, L. et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8
pubmed: 36171284 pmcid: 9534752 doi: 10.1038/s41586-022-05192-0
Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8
pubmed: 36171288 pmcid: 9793890 doi: 10.1038/s41586-022-05257-0
Bonavita, E. et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity 53, 1215–1229.e1218 (2020).
pubmed: 33220234 pmcid: 7772804 doi: 10.1016/j.immuni.2020.10.020
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
pubmed: 26343581 pmcid: 4597191 doi: 10.1016/j.cell.2015.08.015
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
pubmed: 25838374 pmcid: 6295668 doi: 10.1126/science.aaa4967
Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
pubmed: 36477031 doi: 10.1056/NEJMoa2210233
Dafni, U. et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann. Oncol. 30, 1902–1913 (2019).
pubmed: 31566658 doi: 10.1093/annonc/mdz398
Poschke, I. et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology 5, e1240859 (2016).
pubmed: 28123878 pmcid: 5215250 doi: 10.1080/2162402X.2016.1240859
Kristensen, N. P. et al. Neoantigen-reactive CD8
pubmed: 34813506 pmcid: 8759789 doi: 10.1172/JCI150535
Barras, D. et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8
pubmed: 38306416 doi: 10.1126/sciimmunol.adg7995
Chiffelle, J. et al. Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma. Preprint at bioRxiv 10.1101/2023.2007.2021.544585 (2023).
Sreeramkumar, V., Fresno, M. & Cuesta, N. Prostaglandin E2 and T cells: friends or foes? Immunol. Cell Biol. 90, 579–586 (2012).
pubmed: 21946663 doi: 10.1038/icb.2011.75
Lacher, S. B. et al. PGE
Spolski, R., Li, P. & Leonard, W. J. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat. Rev. Immunol. 18, 648–659 (2018).
pubmed: 30089912 doi: 10.1038/s41577-018-0046-y
Noguchi, M. et al. Functional cleavage of the common cytokine receptor gamma chain (γ
pubmed: 9326644 pmcid: 23528 doi: 10.1073/pnas.94.21.11534
Brudvik, K. W. & Tasken, K. Modulation of T cell immune functions by the prostaglandin E
pubmed: 22141738 pmcid: 3417476 doi: 10.1111/j.1476-5381.2011.01800.x
Lone, A. M. et al. Systems approach reveals distinct and shared signaling networks of the four PGE
pubmed: 34609894 doi: 10.1126/scisignal.abc8579
Miyazaki, T. et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266, 1045–1047 (1994).
pubmed: 7973659 doi: 10.1126/science.7973659
Ravnskjaer, K., Madiraju, A. & Montminy, M. Role of the cAMP pathway in glucose and lipid metabolism. Handb. Exp. Pharmacol. 233, 29–49 (2016).
pubmed: 26721678 doi: 10.1007/164_2015_32
Lone, A. M. & Tasken, K. Phosphoproteomics-based characterization of prostaglandin E
pubmed: 33674363 doi: 10.1124/molpharm.120.000170
McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457–495 (2019).
pubmed: 30676822 doi: 10.1146/annurev-immunol-041015-055318
Huang, J. R., Tan, G. M., Li, Y. & Shi, Z. The emerging role of Cables1 in cancer and other diseases. Mol. Pharmacol. 92, 240–245 (2017).
pubmed: 28119482 doi: 10.1124/mol.116.107730
Tan, C. Y. & Hagen, T. Post-translational regulation of mTOR complex 1 in hypoxia and reoxygenation. Cell Signal 25, 1235–1244 (2013).
pubmed: 23416465 doi: 10.1016/j.cellsig.2013.02.012
Lin, Z. et al. The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis. Nat. Commun. 13, 7965 (2022).
pubmed: 36575162 pmcid: 9794750 doi: 10.1038/s41467-022-35707-2
Masid, M., Ataman, M. & Hatzimanikatis, V. Analysis of human metabolism by reducing the complexity of the genome-scale models using redHUMAN. Nat. Commun. 11, 2821 (2020).
pubmed: 32499584 pmcid: 7272419 doi: 10.1038/s41467-020-16549-2
Pandey, V. & Hatzimanikatis, V. Investigating the deregulation of metabolic tasks via minimum network enrichment analysis (MiNEA) as applied to nonalcoholic fatty liver disease using mouse and human omics data. PLoS Comput. Biol. 15, e1006760 (2019).
pubmed: 31002661 pmcid: 6493771 doi: 10.1371/journal.pcbi.1006760
Sanin, D. E. et al. Mitochondrial membrane potential regulates nuclear gene expression in macrophages exposed to prostaglandin E2. Immunity 49, 1021–1033.e1026 (2018).
pubmed: 30566880 pmcid: 7271981 doi: 10.1016/j.immuni.2018.10.011
Yu, Y. R. et al. Disturbed mitochondrial dynamics in CD8
pubmed: 33020660 doi: 10.1038/s41590-020-0793-3
Sukumar, M. et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab. 23, 63–76 (2016).
pubmed: 26674251 doi: 10.1016/j.cmet.2015.11.002
Suhm, T. et al. Mitochondrial translation efficiency controls cytoplasmic protein homeostasis. Cell Metab. 27, 1309–1322.e1306 (2018).
pubmed: 29754951 doi: 10.1016/j.cmet.2018.04.011
Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 701–703 (2016).
pubmed: 27653602 doi: 10.1016/j.immuni.2016.08.009
Hosios, A. M. et al. mTORC1 regulates a lysosome-dependent adaptive shift in intracellular lipid species. Nat. Metab. 4, 1792–1811 (2022).
pubmed: 36536136 pmcid: 9799240 doi: 10.1038/s42255-022-00706-6
Manzo, T. et al. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. 217, e20191920 (2020).
Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8
pubmed: 34102100 pmcid: 9273026 doi: 10.1016/j.immuni.2021.05.003
Nguyen, T. B. et al. DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. Dev. Cell 42, 9–21.e25 (2017).
pubmed: 28697336 pmcid: 5553613 doi: 10.1016/j.devcel.2017.06.003
Nakagawa, Y. et al. CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARα. Sci. Rep. 6, 39182 (2016).
pubmed: 27982131 pmcid: 5159891 doi: 10.1038/srep39182
Qiu, B. et al. HIF2α-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 5, 652–667 (2015).
pubmed: 25829424 pmcid: 4456212 doi: 10.1158/2159-8290.CD-14-1507
Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266–282 (2021).
pubmed: 33495651 pmcid: 8142022 doi: 10.1038/s41580-020-00324-8
Zheng, J. & Conrad, M. The metabolic underpinnings of ferroptosis. Cell Metab. 32, 920–937 (2020).
pubmed: 33217331 doi: 10.1016/j.cmet.2020.10.011
Gebhardt, T., Park, S. L. & Parish, I. A. Stem-like exhausted and memory CD8
pubmed: 37821656 doi: 10.1038/s41568-023-00615-0
Valmori, D. et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160, 1750–1758 (1998).
pubmed: 9469433 doi: 10.4049/jimmunol.160.4.1750
Villa, M. et al. Prostaglandin E
pubmed: 38200005 pmcid: 10781727 doi: 10.1038/s41467-024-44689-2
Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8
pubmed: 34290406 pmcid: 9187974 doi: 10.1038/s41586-021-03704-y
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).
pubmed: 35113651 pmcid: 8996692 doi: 10.1126/science.abl5447
Thumkeo, D. et al. PGE
pubmed: 35675777 doi: 10.1016/j.celrep.2022.110914
Gannon, P. O. et al. Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy 22, 780–791 (2020).
pubmed: 33069566 doi: 10.1016/j.jcyt.2020.07.011
Jiang, J. et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc. Natl Acad. Sci. USA 109, 3149–3154 (2012).
pubmed: 22323596 pmcid: 3286971 doi: 10.1073/pnas.1120195109
Kabashima, K. et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109, 883–893 (2002).
pubmed: 11927615 pmcid: 150928 doi: 10.1172/JCI0214459
Dunsford, L. S., Thoirs, R. H., Rathbone, E. & Patakas, A. in Immuno-Oncology: Cellular and Translational Approaches (ed. Tan, S. L.) 89–101 (Springer, 2020).
Dumauthioz, N. et al. Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell. Mol. Immunol. 18, 1761–1771 (2021).
pubmed: 32055005 doi: 10.1038/s41423-020-0365-3
Genolet, R. et al. TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs. Cell Rep. Methods 3, 100459 (2023).
pubmed: 37159666 pmcid: 10163020 doi: 10.1016/j.crmeth.2023.100459
Miklosi, A. G. et al. Super-resolution microscopical localization of dopamine receptors 1 and 2 in rat hippocampal synaptosomes. Mol. Neurobiol. 55, 4857–4869 (2018).
pubmed: 28735416 doi: 10.1007/s12035-017-0688-y
Rooney, J. P. et al. PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol. Biol. 1241, 23–38 (2015).
pubmed: 25308485 pmcid: 4312664 doi: 10.1007/978-1-4939-1875-1_3
Brunk, E. et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat. Biotechnol. 36, 272–281 (2018).
pubmed: 29457794 pmcid: 5840010 doi: 10.1038/nbt.4072
Pandey, V., Hadadi, N. & Hatzimanikatis, V. Enhanced flux prediction by integrating relative expression and relative metabolite abundance into thermodynamically consistent metabolic models. PLoS Comput. Biol. 15, e1007036 (2019).
pubmed: 31083653 pmcid: 6532942 doi: 10.1371/journal.pcbi.1007036
Pang, Z. et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 49, W388–W396 (2021).
pubmed: 34019663 pmcid: 8265181 doi: 10.1093/nar/gkab382

Auteurs

Matteo Morotti (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Alizee J Grimm (AJ)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Helen Carrasco Hope (HC)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Marion Arnaud (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Mathieu Desbuisson (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Nicolas Rayroux (N)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

David Barras (D)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Maria Masid (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Baptiste Murgues (B)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Bovannak S Chap (BS)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Marco Ongaro (M)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Ioanna A Rota (IA)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Catherine Ronet (C)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Aspram Minasyan (A)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Johanna Chiffelle (J)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Sebastian B Lacher (SB)

Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.

Sara Bobisse (S)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Clément Murgues (C)

Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Eleonora Ghisoni (E)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Khaoula Ouchen (K)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Ribal Bou Mjahed (R)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Fabrizio Benedetti (F)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Naoill Abdellaoui (N)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Riccardo Turrini (R)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.

Philippe O Gannon (PO)

Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Khalil Zaman (K)

Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Patrice Mathevet (P)

Department of Gynaecology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Loic Lelievre (L)

Department of Gynaecology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Isaac Crespo (I)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Marcus Conrad (M)

Institute of Metabolism and Cell Death, Molecular Target and Therapeutics Centre, Helmholtz Munich, Neuherberg, Germany.

Gregory Verdeil (G)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Lana E Kandalaft (LE)

Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Julien Dagher (J)

Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Jesus Corria-Osorio (J)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Marie-Agnes Doucey (MA)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.

Ping-Chih Ho (PC)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Alexandre Harari (A)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Agora Cancer Research Center, Lausanne, Switzerland.

Nicola Vannini (N)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.

Jan P Böttcher (JP)

Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.

Denarda Dangaj Laniti (D)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland. denarda.dangaj@chuv.ch.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. denarda.dangaj@chuv.ch.
Agora Cancer Research Center, Lausanne, Switzerland. denarda.dangaj@chuv.ch.

George Coukos (G)

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland. george.coukos@chuv.ch.
Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland. george.coukos@chuv.ch.
Agora Cancer Research Center, Lausanne, Switzerland. george.coukos@chuv.ch.

Classifications MeSH